A mechanistic gap in our understanding of why JAK inhibitors carry elevated cardiovascular risk may be partly filled by an underappreciated viral culprit. For the millions of patients with rheumatoid arthritis, psoriasis, and other immune-mediated inflammatory diseases now taking JAK inhibitors, the intersection of drug-induced immunosuppression and herpes zoster reactivation could represent a modifiable cardiovascular hazard — one that existing vaccines might help address.
The review, published in Annals of the Rheumatic Diseases, synthesizes epidemiological and mechanistic evidence linking varicella-zoster virus (VZV) reactivation to major adverse cardiovascular events (MACE). Epidemiologic data consistently show a transient spike in MACE in the weeks following a herpes zoster episode. Mechanistically, VZV has demonstrated capacity to infect arterial tissue directly, trigger inflammatory cascades, destabilize atherosclerotic plaques, and promote a prothrombotic vascular environment. Against this backdrop, the authors propose that JAK inhibitors — which blunt antiviral immunity through interference with interferon signaling — may potentiate VZV reactivation frequently enough to meaningfully contribute to the elevated MACE signal observed in the pivotal ORAL Surveillance tofacitinib safety trial. Crucially, the recombinant zoster vaccine (RZV, Shingrix) is associated with reduced MACE incidence in large observational datasets, though randomized trials with hard cardiovascular endpoints remain absent.
This synthesis is analytically significant because it reframes the JAK inhibitor cardiovascular signal — long attributed primarily to the drugs' effects on lipid metabolism and platelet function — as potentially compounded by a viral intermediary that is vaccine-preventable. The hypothesis is biologically coherent and epidemiologically supported, but causal inference is constrained by the observational nature of most cited evidence and the absence of prospectively powered cardiovascular vaccine trials. For a health-conscious readership, the broader implication is notable: chronic viral latency and episodic reactivation may represent an underweighted variable in cardiovascular risk models, particularly for immunocompromised populations. This is an important conceptual advance, though it remains confirmatory in scope rather than paradigm-shifting pending randomized trial data.